# A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201

> **NCT00831649** · PHASE2 · TERMINATED · sponsor: **Biogen**

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** natalizumab

## Key facts

- **NCT ID:** NCT00831649
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-09
- **Primary completion:** 2005-02
- **Final completion:** —
- **Target enrollment:** — (—)
- **Why stopped:** The biological effect seen with natalizumab was not sufficient to warrant further development in RA.
- **Last updated:** 2016-06-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00831649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00831649, "A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00831649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*